Near-term headwinds, with possible run on small biotechs on the horizon
The overall biopharmaceutical deal market began to see a significant slowdown in the fourth quarter of 2022, and from a deal volume standpoint this has carried through into the first quarter of 2023. KPMG has a number of interesting predictions for the biopharma deal space for the remainder of 2023. These include:
Biopharma deal trends outlook for 2023
Download PDFKPMG Deal Advisory distributes a wide selection of thought leadership that highlights the latest M&A issues and trends.